about
Pharmacokinetic comparison to determine the mechanisms underlying the differential efficacies of cationic diamidines against first- and second-stage human African trypanosomiasis.The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models.In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sicknessAntileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diaminesA simple and sensitive assay for eflornithine quantification in rat brain using pre-column derivatization and UPLC-MS/MS detection.A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasmaSAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against Trypanosoma brucei rhodesiense.Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studiesPharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasisPharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus.Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agentsSynthesis and antiprotozoal activity of dicationic 2,6-diphenylpyrazines and aza-analogues.Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement.Effects of lovastatin on the pharmacokinetics of nicardipine in rats.Antileishmanial Efficacy and Pharmacokinetics of DB766-azole Combinations.Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.Pharmacokinetics of drugs in spontaneously or secondary hypertensive rats.Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition.Gender differences in the pharmacokinetics of DA-6034, a derivative of flavonoids, in rats.Correction to Antileishmanial Activity of a Series of N(2),N(4)-Disubstituted Quinazoline-2,4-diamines.Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats.Reduced clearance ofε-acetamidocaproic acid in rats with acute renal failure induced by uranyl nitrateEffects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorsPharmacokinetics and first-pass metabolism of astaxanthin in ratsPharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to ratsDose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: Contribution of gastric first-pass effect to low bioavailability
P50
Q33798222-E1117872-FC6E-450B-AD58-EA18B0D565FAQ33911538-E66794FD-96CC-45E7-A9BE-5218EE7F9841Q34058294-93070B26-BC1D-4AA3-9EDF-A62F059A8DCBQ34435696-4464A1FF-95EB-45AE-9F1D-E78D67A3E54FQ35388587-56CB3071-AF84-48E3-A95B-B10D690C4A08Q35828065-511BE390-D90F-4E5B-975C-E091189B62A5Q35952211-88B05687-B567-44A0-A850-97BBBC051C24Q35996448-996B76F0-6894-4680-B05A-31CDF9371AA4Q36086468-7F47F1D8-48EF-499B-9D9D-FBAEB1441D81Q37263574-CDA19E5F-1E98-4620-ACD0-C9286E9308F2Q37781100-1C72F32D-095E-4CFB-A2CB-95C133B6268DQ38780483-1C750A94-70B1-4E10-8E87-B46DBA7C5BBAQ39099156-0B528E3A-3B24-4D15-8FE8-D50562A45A94Q39516917-1CE85B27-391C-4FE4-B34A-31FFDAC5799FQ42054617-2B3CA84C-E982-4C09-BC5B-35A090770CB7Q42914123-FF4BA68D-8816-4889-B9E4-155096C4D723Q46430242-FD2AE1F0-F9B5-4AF1-88C9-6BAFACDB8E35Q46433873-52A8DED2-A259-493D-8387-0D4A891AF0F2Q46449730-5C1FABFC-1140-4208-81CA-FF790A8B881FQ46514080-0E47836A-E2E1-4313-978C-4D784F273B9CQ46815560-B2696EBB-FA13-4C9C-9CE4-01CECD042C3BQ48698637-9CE786B7-C4CC-428E-A788-A09B708CE169Q51287104-6D65198B-203D-4D5D-98B6-87CE2BEB57A3Q58854618-3B9194AB-D180-4AB2-BEB9-2B2C501B0F80Q58854619-A0DFF20D-C9C2-42CA-92C0-B16A5A379C80Q58854620-EDBB1F0B-B50A-4E4B-8B36-A9DCB1597CD1Q58854622-98FE5C7B-467B-481B-A8E1-A2CCEFC0AE39Q58854625-2D9353B6-BC6B-479B-9B94-549120C8C104
P50
description
researcher ORCID ID = 0000-0003-1751-4975
@en
wetenschapper
@nl
name
Sihyung Yang
@ast
Sihyung Yang
@en
Sihyung Yang
@es
Sihyung Yang
@nl
type
label
Sihyung Yang
@ast
Sihyung Yang
@en
Sihyung Yang
@es
Sihyung Yang
@nl
prefLabel
Sihyung Yang
@ast
Sihyung Yang
@en
Sihyung Yang
@es
Sihyung Yang
@nl
P106
P31
P496
0000-0003-1751-4975